Napster Cofounder Launches Cancer Initiative

Billionaire Silicon Valley entrepreneur Sean Parker donates $250 million to unite the cancer research community around the common goal of developing new immunotherapies.

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

WIKIMEDIA, AMAGERThe Parker Foundation, a philanthropic organization created by Napster cofounder Sean Parker, is giving a big boost to cancer research, with a $250 million donation meant to increase collaboration among scientists and institutions focused on immunotherapy research. The foundation announced its plan to launch the Parker Institute for Cancer Immunotherapy today (April 13).

Parker’s cancer immunotherapy initiative will bring together more than 300 scientists in 40 labs at major research institutions, including Stanford University, the University of California, San Francisco (UCSF), the University of Pennsylvania, and Memorial Sloan Kettering Cancer Center, among others. “Cancer immunotherapy is such an incredibly complex field, and for every answer it seems to pose 10 more questions,” Parker told The Washington Post. “I’m an entrepreneur so I wish some of these questions had been answered yesterday.”

The researchers and institutions will share data and intellectual property on innovations that arise from the Parker Foundation-funded work. “The Parker Institute’s goal is to accelerate the development of breakthrough immune therapies capable of turning cancer into a curable disease by ensuring the coordination and collaboration of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Keywords

Meet the Author

  • Bob Grant

    From 2017 to 2022, Bob Grant was Editor in Chief of The Scientist, where he started in 2007 as a Staff Writer.
Share
May digest 2025 cover
May 2025, Issue 1

Study Confirms Safety of Genetically Modified T Cells

A long-term study of nearly 800 patients demonstrated a strong safety profile for T cells engineered with viral vectors.

View this Issue
Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Detecting Residual Cell Line-Derived DNA with Droplet Digital PCR

Bio-Rad
How technology makes PCR instruments easier to use.

Making Real-Time PCR More Straightforward

Thermo Fisher Logo
Characterizing Immune Memory to COVID-19 Vaccination

Characterizing Immune Memory to COVID-19 Vaccination

10X Genomics
Optimize PCR assays with true linear temperature gradients

Applied Biosystems™ VeriFlex™ System: True Temperature Control for PCR Protocols

Thermo Fisher Logo

Products

The Scientist Placeholder Image

Biotium Launches New Phalloidin Conjugates with Extended F-actin Staining Stability for Greater Imaging Flexibility

Leica Microsystems Logo

Latest AI software simplifies image analysis and speeds up insights for scientists

BioSkryb Genomics Logo

BioSkryb Genomics and Tecan introduce a single-cell multiomics workflow for sequencing-ready libraries in under ten hours

iStock

Agilent BioTek Cytation C10 Confocal Imaging Reader

agilent technologies logo